What NovaCina does

NovaCina is described in its firmographic profile as a private Australian company providing premium sterile liquid pharmaceutical contract manufacturing services, headquartered in Bentley with a reported workforce of 251-500 employees and a founding year of 2023. The functional positioning implies a B2B contract development and manufacturing organization (CDMO) offering aseptic fill-finish capacity for liquid dosage forms (vials, ampoules, syringes, or IV bags) to pharmaceutical sponsor clients. The revenue model is implicitly contract-based, with the company monetizing validated sterile manufacturing capacity, quality systems, and regulatory compliance infrastructure on a per-batch or per-campaign basis; however, no specific pricing structure, contract terms, customer segmentation, or go-to-market mechanics are disclosed in the supplied source data.

The company's technology and product surface is essentially undefined in the available source data: no product catalog, process platform details (isolator vs. RABS filling, lyophilization, blow-fill-seal), regulatory filings (TGA, FDA, EMA registrations), certifications, or site capability disclosures are available. The sole confirmed technical claim is the high-level service category of "premium sterile liquid pharmaceutical contract manufacturing."

A material inconsistency must be flagged: while the firmographic record indicates an operating entity of 251-500 employees founded in 2023, the company's web domain (novacina.co) is currently parked at GoDaddy with no active corporate website. This combination — a sizeable newly-founded sterile CDMO with no functioning public web presence — is unusual and warrants verification. It may reflect formation via acquisition of an existing facility and workforce (with deferred marketing infrastructure), a corporate restructuring or transition event, or an incomplete build-out. No funding rounds, M&A activity, leadership changes, regulatory actions, or partnership announcements are present in the supplied source data.

Name

NovaCina

Website

https://novacina.co

Company type

Private

Founded year

2023

Operating status

Closed

Headcount range

251–500 employees

Short description

NovaCina is an Australian private sterile liquid pharmaceutical contract manufacturer (CDMO) headquartered in Bentley, founded in 2023 with 251-500 employees, serving pharmaceutical sponsor clients requiring aseptic fill-finish capacity. Its public web presence is currently inactive.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Sterile pharmaceutical manufacturing
• Contract manufacturing services
• Liquid drug manufacturing
• Aseptic fill finish
• Pharmaceutical CMO services

Headquarters

HQ city

Bentley

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Core offering

NovaCina provides premium sterile liquid pharmaceutical contract manufacturing services. The company produces sterile liquid dosage forms for pharmaceutical clients on a contract basis, with operations anchored in Bentley, Australia. Its function is to serve as an outsourced manufacturing partner for pharma companies requiring aseptic fill-finish capacity.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Liquid Pharmaceutical Contract Manufacturing Outsourced aseptic fill-finish manufacturing of sterile liquid pharmaceutical dosage forms, delivered on a contract basis to pharmaceutical and biopharmaceutical clients requiring GMP-compliant production capacity.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Almac Group: Global CDMO offering sterile and aseptic manufacturing services for liquid and lyophilized drug products, comparable in technical scope and target customer base.
• Recipharm: European-based CDMO providing sterile fill-finish and aseptic manufacturing for liquid and lyophilized injectables, directly competing for the same pharmaceutical outsourcing contracts.
• CordenPharma: Full-service CDMO providing sterile injectable fill-finish and aseptic manufacturing alongside peptide and API capabilities, directly overlapping with NovaCina's sterile liquid focus.
• Aenova Group: European pharmaceutical CDMO with sterile liquid and aseptic fill-finish capabilities serving small molecule and biologic sponsors, directly comparable in service offering.
• IDT Biologika: CDMO offering sterile liquid fill-finish and aseptic manufacturing for vaccines and biologics, directly comparable in technical capability and customer base.
• PCI Pharma Services: Global sterile injectable and liquid contract manufacturer offering aseptic fill-finish, lyophilization, and packaging services to pharma and biotech clients, directly comparable in core sterile CDMO capabilities.

Broad incumbents

• Lonza: Major global CDMO offering sterile fill-finish and aseptic manufacturing alongside large-scale biologics and API services, providing overlapping sterile capabilities with much broader scale.
• Patheon (Thermo Fisher Scientific): Global pharma services division offering commercial-scale sterile fill-finish, aseptic manufacturing, and finished dosage services, an incumbent across the broader sterile CDMO value chain.
• Catalent: One of the largest global CDMOs with a broad sterile injectable fill-finish franchise across softgels, biologics, and aseptic manufacturing, providing overlapping capability but as part of a much wider portfolio.

Regional players

• Bora Pharmaceuticals: Asia-Pacific headquartered CDMO with sterile and aseptic fill-finish capabilities, comparable in offering but primarily serving a different regional customer base than an Australian operator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaCina